BGF Policy Statement on the Antagene Histio Sarcoma Test

After consideration of the available information in regard to the Antagene Histiocytic Sarcoma test, The Berner-Garde Foundation (BGF) has determined that it will display only that an individual dog has been tested. The resulting index A, B or C will not be displayed. However, BGF will store the results. BGF supports the testing of BMDs for ongoing research. However, key data for this research has not been shared or peer reviewed. When scientific information on the validity of the test as a risk prediction tool becomes available the BGF will re-assess its position on public display of the index.

This policy is consistent with several countries in Europe.

This policy will be effective on August 1, 2020.

For more information on this test visit:

Or visit Antagene at